GPX4 and colorectal cancer: An increasing number of studies in recent years have shown that inducing ferroptosis in colorectal cancer cells by increasing intracellular Fe2+ and ROS levels, decreasing the levels of the antioxidant glutathione (GSH), or inactivating GPX4 can contribute to the clinical treatment of colorectal cancer, while inhibiting ferroptosis may lead to tumor progression and therapeutic resistance in colorectal cancer [25, 26].